Orion Corporation: Managers’ transactions – Agendum Oy

ORION CORPORATION
MANAGERS’ TRANSACTIONS
11 MAY 2023 at 15.30 EEST
        

Orion Corporation: Managers’ transactions – Agendum Oy

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Agendum Oy
Position: Closely associated person
(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer
Name: Mikael Silvennoinen
Position: Member of the Board
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 31439/4/6

____________________________________________
Transaction date: 2023-05-09
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 85 Unit price: 43.22 EUR
(2): Volume: 36 Unit price: 43.22 EUR
(3): Volume: 151 Unit price: 43.22 EUR
(4): Volume: 151 Unit price: 43.22 EUR
(5): Volume: 175 Unit price: 43.22 EUR
(6): Volume: 120 Unit price: 43.21 EUR
(7): Volume: 151 Unit price: 43.21 EUR
(8): Volume: 63 Unit price: 43.21 EUR
(9): Volume: 175 Unit price: 43.21 EUR
(10): Volume: 2 Unit price: 43.19 EUR

Aggregated transactions (10):
Volume: 1109 Volume weighted average price: 43.21536 EUR
____________________________________________
Transaction date: 2023-05-09
Venue: TQEX
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 38 Unit price: 43.21 EUR

Aggregated transactions (1):
Volume: 38 Volume weighted average price: 43.21 EUR
____________________________________________
Transaction date: 2023-05-09
Venue: CEUX
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 21 Unit price: 43.21 EUR
(2): Volume: 154 Unit price: 43.21 EUR
(3): Volume: 21 Unit price: 43.2 EUR
(4): Volume: 154 Unit price: 43.2 EUR
(5): Volume: 30 Unit price: 43.19 EUR

Aggregated transactions (5):
Volume: 380 Volume weighted average price: 43.20382 EUR
____________________________________________
Transaction date: 2023-05-09
Venue: AQEU
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 125 Unit price: 43.22 EUR
(2): Volume: 107 Unit price: 43.2 EUR

Aggregated transactions (2):
Volume: 232 Volume weighted average price: 43.21078 EUR

Orion Corporation

Liisa Hurme

President and CEO

    Olli Huotari

SVP, Corporate Functions

 

                                                

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion’s net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

4 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

5 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

5 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

6 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

8 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

8 hours ago